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PreviewsAntidepressants and the
Monoamine Masquerade
Neurotransmitter transporters have long been known
to recognize related compounds as substrates, re-
sulting in the accumulation and release of so-called
“false transmitters.” In this issue of Neuron, Zhou et
al. show that when serotonin levels are elevated by
inhibition of either serotonin reuptake or of mono-
amine oxidase, dopamine neurons accumulate sero-
tonin. The results suggest that release of serotonin
by dopamine neurons may contribute to the effects
of multiple major classes of antidepressants.
Plasma membrane uptake systems have long been
known to accumulate different neurotransmitters some-
what promiscuously. Indeed, the initial discovery of
plasma membrane transmitter uptake, in 1958 by Bar-
bara Hughes, a fellow in Bernard Brodie’s laboratory at
the National Heart Institute (Hughes and Brodie, 1959;
Hughes et al., 1958), included evidence that the mono-
amine transmitters (serotonin and the catecholamines)
are recognized as substrates by the same reuptake
system.
Hughes and Brodie examined the uptake of seroto-
nin, epinephrine, and norepinephrine in guinea pig
platelets. The uptake of serotonin was more rapid than
for the catecholamines, but all were substrates for the
same system, as indicated by inhibition of accumula-
tion by reserpine, a plant extract used to treat mental
illness in India that was eventually found to inhibit
specifically the uptake of monoamines into secretory
vesicles. Although we now know that reserpine does
not inhibit plasma membrane uptake, Hughes correctly
concluded that there was “an endergonic mechanism
that rapidly extracts serotonin from the surrounding
medium against a concentration gradient.”
An independent line of early investigation led to the
so-called “false transmitter hypothesis,” which sug-
gested that different monoamines could be packaged
into the same synaptic vesicle. Once plasma mem-
brane transporters have accumulated monoamines into
the cytosol, the transmitters are either taken up into
synaptic vesicles or metabolized by monoamine oxi-
dase (MAO). The first widely prescribed class of anti-
depressants were MAO inhibitors, which, as might be
predicted, enhanced serotonin and catecholamine
levels. Clinicians noted, however, that MAO inhibitors
sometimes caused hypertension in patients who had
consumed red wine, beer, and cheese. Irwin Kopin
(Kopin, 1968) suggested that nonneurotransmitter
monoamines such as tyramine, a decarboxylated tyro-
sine metabolite that is normally metabolized by MAO,
could act as false transmitters that would be accumu-
lated into vesicles and then released. Tyramine, whichcan be produced at high levels by yeast and microbes
during the manufacture of these foods, and its metabo-
lite octopamine indeed turned out to be the culprits re-
sponsible for hypertension in cheese-eating patients
(Blackwell and Mabbitt, 1965).
A molecular basis of false transmitter action became
clear after the identification and cloning of most of the
plasma membrane and vesicular neurotransmitter
transporters in the early 1990s. The dopamine uptake
transporter (DAT) is exclusively expressed in neurons
that synthesize and release dopamine, the norepineph-
rine transporter (NET) by noradrenergic neurons, and
the serotonin transporter (SERT) by serotonergic neu-
rons, and the proximity of release and reuptake sites
presumably helps to load the correct transmitter into
each neuron’s synaptic vesicles. Consistent with Bar-
bara Hughes’ early report, however, each monoamine
transporter accumulates the monoamines made by
other cells. For example, NET has a higher apparent
affinity for dopamine than norepinephrine (Gu et al.,
1994). Mice lacking DAT still self-administer cocaine
(Rocha et al., 1998), suggesting that NET or SERT can
contribute to dopamine’s clearance.
In contrast to the selective distribution of the plasma
membrane transporters, the vesicular monoamine
transporter 2 (VMAT2) is expressed by all monoamine
neurons. Both VMAT2 and VMAT1 (expressed in non-
neural cells) accumulate serotonin and catecholamines,
as well as classic false transmitters such as tyramine.
Moreover, they recognize serotonin with at least a
3-fold higher apparent affinity than dopamine, but
transport serotonin more slowly (Peter et al., 1994). Al-
though the significance of these differences in sub-
strate recognition has remained unclear, they are con-
served across species (Erickson and Eiden, 1993) and
raise the possibility that serotonin might be able both
to accumulate in the synaptic vesicles of dopamine
neurons and to inhibit the packaging of dopamine.
There are several reports of serotonin acting as a false
transmitter in dopamine terminals following pharmaco-
logical interventions, as well as evidence suggesting
that serotonin may normally act as a false transmitter
at dopamine terminals in the intermediate lobe of the
pituitary (Vanhatalo and Soinila, 1995).
Although the plasma membrane monoamine trans-
porters show some promiscuity in substrate recogni-
tion, the clinical efficacy of many antidepressants indi-
cates that the transporters each have distinct roles. The
“tricyclic” desipramine (Norpramin) is particularly se-
lective for NE, and paroxetine (Paxil) and fluoxetine
(Prozac) are particularly selective for SERT. Interest-
ingly, selective DAT inhibitors have not emerged as ef-
fective antidepressants, raising the possibility that
MAO inhibitors and serotonin-selective reuptake inhibi-
tors (SSRIs) result in the accumulation of serotonin as a
false transmitter by dopamine neurons. Consistent with
this possibility, serotonin accumulation by dopamine
neurons was observed in mice lacking the SERT gene
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2and wild-type animals treated with paroxetine (Zhou et D
al., 2002). Serotonin uptake by catecholamine neurons 1
was also observed in mice lacking one of the mono-
amine oxidase genes (MAO-A) (Cases et al., 1998). C
The evidence that antidepressants induce serotonin D
accumulation by dopamine neurons has now been sig- N
nificantly advanced by a study in this issue of Neuron N
from John Dani’s laboratory (Zhou et al., 2005). The in- 2
vestigators adapted rapid electrochemical measure- U
ments of evoked dopamine and serotonin release in S
acute “horizontal” slices that encompass a portion of S
the innervating axons from midbrain dopamine neu-
rons, and their primary target area, the striatum, where
Sboth dopamine and DAT are present at far higher levels
than serotonin and SERT. To record dopamine and se-
Brotonin release evoked by electrical stimuli, they used
Ccyclic voltammetry, in which ramp voltages are applied
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to a carbon fiber electrode and that to some extent dif- 6
ferentiates the transmitters on the basis of the I-V rela-
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tionships of their oxidation and reduction peaks. They 2
further noted that the serotonin component could be G
identified, due to the relatively greater adsorption of se- 7
rotonin to the carbon surface, simply by analyzing a H
later point during the signal’s falling phase. 9
When the investigators exposed striatal tissue to flu- H
oxetine in the presence of nisoxetine, a specific NET 1
inhibitor, evoked serotonin release increased, whereas K
dopamine release decreased. Serotonin may thus act P
as a false transmitter after exposure to SSRIs. The sig- B
nal, however, represents the release of transmitter from R
Ghundreds of synaptic vesicle fusion events and could
1alternatively reflect an enhanced release of serotonin
Vfrom its native terminals. They addressed this possi-
Zbility by examining nonevoked spontaneous release
1events, which are much smaller and likely reflect
Ztransmitter release from dozens of synaptic vesicles at
Jsynaptic varicosities along the incoming dopamine fi-
bers. Each of these smaller events likewise contained D
both dopamine and serotonin, further evidence consis-
tent with corelease. Perhaps more convincingly, fluoxe-
tine’s effect was inhibited by the selective DAT inhibitor
GBR12909, as would be predicted if the serotonin was
accumulated by DAT. The authors thus conclude that
when SERT is blocked by SSRIs, serotonin acts as a
false transmitter in dopamine neurons. Experiments in
vivo suggest that the effect may require several days
of administration, which could underlie the well-known
delay in full therapeutic benefit of these drugs. And to
bring the story full circle, they found that the MAO in-
hibitor clorgyline further promotes serotonin uptake
and release by dopamine neurons.
The data clearly indicate that, at least under some
conditions, both major classes of antidepressants
cause serotonin to act as false transmitter in dopamine
neurons. It is not yet known if such serotonin release
by dopamine neurons contributes to the therapeutic ef-
fect of these agents, and it would be very interesting to
know whether inhibition of DAT blocks the antidepres-
sant effects of SSRIs. The Dani lab, in the meantime,
can take credit for an elegant proof of a phenomenon
that may underlie the effects, and perhaps the delayed
response, for the many patients who take these drugs.
And well in time for the 50th anniversary of Hughes’
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